Thelansis launches its Charcot-Marie-Tooth (CMT) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026, offering pharma and biotech decision-makers a clear view of the evolving pipeline, critical gaps in care, and the product profiles most likely to win